Identification
- Summary
Tromethamine is a proton acceptor used for the prevention and correction of metabolic acidosis associated with various clinical conditions, such as cardiac bypass surgery.
- Generic Name
- Tromethamine
- DrugBank Accession Number
- DB03754
- Background
An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Tromethamine (DB03754)
- Weight
- Average: 121.135
Monoisotopic: 121.073893223 - Chemical Formula
- C4H11NO3
- Synonyms
- 1,1,1-tris(hydroxymethyl)methanamine
- 2-Amino-2-(hydroxymethyl)-1,3-propanediol
- aminotris(hydroxymethyl)methane
- THAM
- Tris
- Tris(hydroxymethyl)aminomethane
- Trometamol
- Tromethamine
- External IDs
- NSC-6365
Pharmacology
- Indication
For the prevention and correction of metabolic acidosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Metabolic acidosis •••••••••••• •••••••••• •••••••• Treatment of Metabolic acidosis •••••••••••• •••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAmyloid beta A4 protein inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareFlecainide The serum concentration of Flecainide can be increased when it is combined with Tromethamine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Tham Injection, solution 3.6 g/100mL Intravenous Hospira, Inc. 2020-06-24 Not applicable US 
Tham Solution 36mg/ml Solution 36 mg / mL Intravenous Hospira Healthcare Ulc 1972-12-31 2018-10-03 Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Sooryehan Hyo Fermented Sun Block Tromethamine (2.63 mL/100mL) + Amiloxate (1.6 mL/100mL) + Bemotrizinol (1 mL/100mL) + Diethylamino hydroxybenzoyl hexyl benzoate (1 mL/100mL) + Ensulizole (3.9 mL/100mL) + Octinoxate (7 mL/100mL) + Titanium dioxide (2.52 mL/100mL) Cream Topical Lg Household & Health Care Ltd. 2011-09-27 Not applicable US
Categories
- ATC Codes
- B05XX02 — Trometamol
- B05XX — Other i.v. solution additives
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Alcohols
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Buffers
- Compounds used in a research, industrial, or household setting
- Excipients
- Glycols
- I.V. Solution Additives
- i.v. Solutions
- Laboratory Chemicals
- Pharmaceutic Aids
- Pharmaceutical Preparations
- Pharmaceutical Vehicles
- Propylene Glycols
- Solutions Affecting the Electrolyte Balance
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- 1,2-aminoalcohols
- Alternative Parents
- Primary alcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
- Substituents
- 1,2-aminoalcohol / Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Organopnictogen compound / Primary alcohol / Primary aliphatic amine / Primary amine
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- primary amino compound, triol (CHEBI:9754) / a small molecule (TRIS)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 023C2WHX2V
- CAS number
- 77-86-1
- InChI Key
- LENZDBCJOHFCAS-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
- IUPAC Name
- 2-amino-2-(hydroxymethyl)propane-1,3-diol
- SMILES
- NC(CO)(CO)CO
References
- Synthesis Reference
Jean Bourguignon, Marcel-Xavier Sion, Michel Moreau, "Preparation of tris(hydroxymethyl)aminomethane." U.S. Patent US4233245, issued August, 1959.
US4233245- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0240288
- KEGG Drug
- D00396
- KEGG Compound
- C07182
- PubChem Compound
- 6503
- PubChem Substance
- 46506027
- ChemSpider
- 6257
- 10865
- ChEBI
- 9754
- ChEMBL
- CHEMBL1200391
- ZINC
- ZINC000000896695
- PDBe Ligand
- TRS
- Wikipedia
- Tris
- FDA label
- Download (88.7 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Anaplastic Medulloblastoma / Medulloblastomas / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor 1 3 Active Not Recruiting Treatment Childhood Atypical Teratoid/Rhabdoid Tumor 1 3 Active Not Recruiting Treatment Extraocular Retinoblastoma 1 3 Active Not Recruiting Treatment Ganglioneuroblastoma / Neuroblastoma (NB) 1 3 Completed Prevention Respiratory Syncytial Virus (RSV) Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Topical Injection, solution Intravenous 3.6 g/100mL Solution Intravenous 36 mg / mL Injection, solution Intravenous; Parenteral 3.6 % Solution Intravenous 3.6 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 695.0 mg/mL ALOGPS logP -2.1 ALOGPS logP -2.7 Chemaxon logS 0.76 ALOGPS pKa (Strongest Acidic) 14.16 Chemaxon pKa (Strongest Basic) 8.95 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 86.71 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 28.36 m3·mol-1 Chemaxon Polarizability 12.02 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.52 Blood Brain Barrier - 0.6989 Caco-2 permeable - 0.6613 P-glycoprotein substrate Non-substrate 0.6664 P-glycoprotein inhibitor I Non-inhibitor 0.9749 P-glycoprotein inhibitor II Non-inhibitor 0.9671 Renal organic cation transporter Non-inhibitor 0.9239 CYP450 2C9 substrate Non-substrate 0.8432 CYP450 2D6 substrate Non-substrate 0.8337 CYP450 3A4 substrate Non-substrate 0.8096 CYP450 1A2 substrate Non-inhibitor 0.8179 CYP450 2C9 inhibitor Non-inhibitor 0.9095 CYP450 2D6 inhibitor Non-inhibitor 0.9027 CYP450 2C19 inhibitor Non-inhibitor 0.895 CYP450 3A4 inhibitor Non-inhibitor 0.9568 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9686 Ames test Non AMES toxic 0.9257 Carcinogenicity Non-carcinogens 0.7844 Biodegradation Ready biodegradable 0.582 Rat acute toxicity 1.5129 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9739 hERG inhibition (predictor II) Non-inhibitor 0.9664
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 120.305657 predictedDarkChem Lite v0.1.0 [M-H]- 127.053345 predictedDeepCCS 1.0 (2019) [M+H]+ 120.570657 predictedDarkChem Lite v0.1.0 [M+H]+ 129.05507 predictedDeepCCS 1.0 (2019) [M+Na]+ 120.176757 predictedDarkChem Lite v0.1.0 [M+Na]+ 137.35686 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transition metal ion binding
- Specific Function
- Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
- Gene Name
- APP
- Uniprot ID
- P05067
- Uniprot Name
- Amyloid beta A4 protein
- Molecular Weight
- 86942.715 Da
References
- Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):567-71. doi: 10.1073/pnas.90.2.567. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55